J Korean Med Assoc.  2018 Apr;61(4):241-247. 10.5124/jkma.2018.61.4.241.

Interpretation of puzzling thyroid function tests

• Yoon JH
• Kang HC

• KMID: 2409043
• DOI: http://doi.org/10.5124/jkma.2018.61.4.241

Abstract

With the generalized use of highly sensitive thyroid stimulating hormone (TSH) and free thyroid hormone assays, most thyroid function tests (TFTs) are straightforward to interpret and confirm the clinical impressions of thyroid diseases. However, in some patients, TFT results can be perplexing because the clinical picture is not compatible with the tests or because TSH and free T4 are discordant with each other. Optimizing the interpretation of TFTs requires a complete knowledge of thyroid hormone homeostasis, an understanding of the range of tests available to the clinician, and the ability to interpret biochemical abnormalities in the context of the patient's clinical thyroid status. The common etiologic factors causing puzzling TFT results include intercurrent illness (sick euthyroid syndrome), drugs, alteration in normal physiology (pregnancy), hypothalamic-pituitary diseases, rare genetic disorders, and assay interference. Sick euthyroid syndrome is the most common cause of TFT abnormalities encountered in the hospital. In hypothalamic-pituitary diseases, TSH levels are unreliable. Therefore, it is not uncommon to see marginally high TSH levels in central hypothyroidism. Drugs may be the culprit of TFT abnormalities through various mechanisms. Patients with inappropriate TSH levels need a differential diagnosis between TSH-secreting pituitary adenoma and resistance to thyroid hormone. Sellar magnetic resonance imaging, serum α-subunit levels, serum sex hormone-binding globulin levels, a thyrotropin-releasing hormone stimulation test, trial of somatostatin analogues, and TR-β sequencing are helpful for the diagnosis, but it may be challenging. TFTs should be interpreted based on the clinical context of the patient, not just the numbers and reference ranges of the tests, to avoid various pitfalls of TFTs and unnecessary costly evaluations and therapies.

Keyword

Thyroid function tests; Diagnostic errors; Hypothyroidism; Hyperthyroidism

MeSH Terms

Diagnosis
Diagnosis, Differential
Diagnostic Errors
Euthyroid Sick Syndromes
Homeostasis
Humans
Hyperthyroidism
Hypothyroidism
Magnetic Resonance Imaging
Physiology
Pituitary Neoplasms
Rare Diseases
Reference Values
Sex Hormone-Binding Globulin
Somatostatin
Thyroid Diseases
Thyroid Function Tests*
Thyroid Gland*
Thyrotropin
Thyrotropin-Releasing Hormone
Sex Hormone-Binding Globulin
Somatostatin
Thyrotropin
Thyrotropin-Releasing Hormone

Reference

1. Dayan CM. Interpretation of thyroid function tests. Lancet. 2001; 357:619–624.

2. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt JR. Guidelines Committee, National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003; 13:3–126.

3. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017; 27:315–389.

4. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. Lancet Diabetes Endocrinol. 2015; 3:816–825.

5. Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med. 1995; 333:1688–1694.

6. Rose SR, Lustig RH, Pitukcheewanont P, Broome DC, Burghen GA, Li H, Hudson MM, Kun LE, Heideman RL. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab. 1999; 84:4472–4479.

7. Yi KH, Moon JH, Kim IJ, Bom HS, Lee J, Chung WY, Chung JH, Shong YK. The diagnosis and management of hyperthyroidism consensus: report of the Korean Thyroid Association. J Korean Thyroid Assoc. 2013; 6:1–11.

8. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016; 388:906–918.

9. Smith TJ, Hegedus L. Graves’ disease. N Engl J Med. 2016; 375:1552–1565.

10. Ralls PW, Mayekawa DS, Lee KP, Colletti PM, Radin DR, Boswell WD, Halls JM. Color-flow Doppler sonography in Graves disease: “thyroid inferno”. AJR Am J Roentgenol. 1988; 150:781–784.

11. Lee SM, Kim SK, Hahm JR, Jung JH, Kim HS, Kim S, Chung SI, Choi BH, Jung TS. Differential diagnostic value of total T3/free T4 ratio in Graves’ disease and painless thyroiditis presenting thyrotoxicosis. Endocrinol Metab. 2012; 27:121–125.

12. Toft AD. Clinical practice: subclinical hyperthyroidism. N Engl J Med. 2001; 345:512–516.

13. Lania A, Persani L, Beck-Peccoz P. Central hypothyroidism. Pituitary. 2008; 11:181–186.

14. Persani L, Ferretti E, Borgato S, Faglia G, Beck-Peccoz P. Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J Clin Endocrinol Metab. 2000; 85:3631–3635.

15. Abucham J, Castro V, Maccagnan P, Vieira JG. Increased thyrotrophin levels and loss of the nocturnal thyrotrophin surge in Sheehan's syndrome. Clin Endocrinol (Oxf). 1997; 47:515–522.

16. Oliveira JH, Persani L, Beck-Peccoz P, Abucham J. Investigating the paradox of hypothyroidism and increased serum thyrotropin (TSH) levels in Sheehan's syndrome: characterization of TSH carbohydrate content and bioactivity. J Clin Endocrinol Metab. 2001; 86:1694–1699.

17. Erfurth EM, Hedner P. Thyroid hormone metabolism in thyroid disease as reflected by the ratio of serum triiodothyronine to thyroxine. J Endocrinol Invest. 1986; 9:407–412.

18. Peeters RP. Subclinical hypothyroidism. N Engl J Med. 2017; 376:2556–2565.

19. Beck-Peccoz P, Lania A, Beckers A, Chatterjee K, Wemeau JL. 2013 European Thyroid Association guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors. Eur Thyroid J. 2013; 2:76–82.

20. Ortiga-Carvalho TM, Sidhaye AR, Wondisford FE. Thyroid hormone receptors and resistance to thyroid hormone disorders. Nat Rev Endocrinol. 2014; 10:582–591.

21. Kim HK, Kim D, Yoo EH, Lee JI, Jang HW, Tan AH, Hur KY, Kim JH, Kim KW, Chung JH, Kim SW. A case of resistance to thyroid hormone with thyroid cancer. J Korean Med Sci. 2010; 25:1368–1371.

22. Kim JH, Park TS, Baek HS, Kim GH, Yoo HW, Park JH. A newly identified insertion mutation in the thyroid hormone receptor-beta gene in a Korean family with generalized thyroid hormone resistance. J Korean Med Sci. 2007; 22:560–563.

23. Yi KH, Kim KW, Yim CH, Jung ED, Chung JH, Chung HK, Hong SC, Chung JH. Guidelines for the diagnosis and management of thyroid disease during pregnancy and postpartum. J Korean Thyroid Assoc. 2014; 7:7–39.

24. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS, Sawka AM. American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014; 24:1670–1751.

25. Kim HI, Kim TH, Kim H, Kim YN, Jang HW, Chung JH, Moon SM, Jhun BW, Lee H, Koh WJ, Kim SW. Effect of rifampin on thyroid function test in patients on levothyroxine medication. PLoS One. 2017; 12:e0169775.

26. Illouz F, Braun D, Briet C, Schweizer U, Rodien P. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol. 2014; 171:R91–R99.

27. Joshi MN, Whitelaw BC, Palomar MT, Wu Y, Carroll PV. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf). 2016; 85:331–339.

28. Elston MS, Sehgal S, Du Toit S, Yarndley T, Conaglen JV. Factitious Graves’ disease due to biotin immunoassay interference-a case and review of the literature. J Clin Endocrinol Metab. 2016; 101:3251–3255.

29. Kummer S, Hermsen D, Distelmaier F. Biotin treatment mimicking Graves’ disease. N Engl J Med. 2016; 375:704–706.